| The Effect of Co-Administration of Rebamipide on the Expression of Serum Gastrin in Long-term Proton Pump Inhibitor Users: A Prospective Pilot Study |
|
Eun Joo Im, Byung Wook Kim, Joon Sung Kim, Hae Mi Lee, Jong In Kim, Bong Koo Kang, Jeong Seon Ji, Bo In Lee, Hwang Choi |
|
Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea College of Medicine, Incheon, Korea. gastro@catholic.ac.kr |
| 장기간 양성자펌프억제제 투여시 레바미피드 병용투여가 혈청 가스트린(Gastrin) 발현에 미치는 영향: 전향적 예비 연구 |
|
임은주, 김병욱, 김준성, 이해미, 김종인, 강봉구, 지정선, 이보인, 최 황 |
|
가톨릭대학교 의과대학 인천성모병원 소화기내과학교실 |
|
|
| Abstract |
BACKGROUND/AIMS
In one animal study, co-administration of rebamipide with proton pump inhibitors (PPIs) could suppress hypergastrinemia but there have been no such reports on humans. The aim of this study was to evaluate whether rebamipide could prevent hypergastrinemia in long-term PPI users. MATERIALS AND METHODS: Patients who were diagnosed with reflux esophagitis endoscopically were enrolled in this study. In the control group, lansoprazole 30 mg was administered for 8 weeks and in the rebamipide group, lansoprazole 30 mg with rebamipide 300 mg was administered for 8 weeks. Serum gastrin level was checked before and after administration of the drugs. RESULTS: Thirty patients were enrolled in this study. The control group included 17 patients and the rebamipide group included 13 patients. The gastrin level was elevated in the control group (28.4 pg/mL) compared to the rebamipide group (38.5 pg/mL). However, the gastrin level was decreased in 3 patients in the rebamipide group (23.1%) compared to 2 patients in the control group (11.8%). CONCLUSIONS: Not all patients who are taking PPIs develop hypergastrinemia. Co-administration of rebamipide with PPI does not affect the serum gastrin level. |
| Key Words:
Gastrins; Proton pump inhibitors; Rebamipide |
|
PDF Links
Full text via DOI
Download Citation
